Clinical Trial Update: Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing ticagrelor 60 mg versus ticagrelor 90 mg in elderly patients with acute coronary syndrome has completed recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Myocardial Infarction
• Non-st-elevation Myocardial Infarction
• St-elevation Myocardial Infarction

Drugs mentioned

• Ticagrelor 90 mg (ticagrelor)
• ticagrelor 60 mg (ticagrelor)

Snippet

Sponsor: Federico II University | Conditions: Acute Coronary Syndrome, STEMI | Phase 3 | Status: COMPLETED